Physician profile
Hung-Sam Lee
NPI 1730210949
$8,592.06
in general payments reported to CMS, 2019-2025
26 companies · $670 in 2025
The $670 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,432 · 2020: $574 · 2021: $1,472 · 2022: $1,430 · 2023: $1,913 · 2024: $1,101 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,595 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,595.28 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,196.93 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $919.38 | 2019-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $753.45 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $627.86 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $428.35 | 2021-2024 | |
| Pfizer INC. | $426.84 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $284.01 | 2023-2025 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $254.70 | 2021-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $251.08 | 2019-2025 | Watchman Flx, Watchman Access System |
| Edwards Lifesciences Corporation | $225.83 | 2022-2025 | Sapien 3 Ultra Resilia |
| Amarin Pharma, INC. | $225.67 | 2019-2023 | |
| Gilead Sciences, INC. | $216.91 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $127.36 | 2023-2024 | Inpefa |
| Novo Nordisk INC | $113.57 | 2020-2021 | |
| Heartflow, INC. | $100.27 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $82.40 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.31 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.82 | 2019-2021 | |
| Medicomp INC | $45.30 | 2022 | |
| Davol INC. | $41.95 | 2019 | |
| Amgen INC. | $37.55 | 2022 | |
| Abbott Laboratories | $25.52 | 2021 | |
| Scpharmaceuticals INC. | $25.23 | 2025 | |
| Astellas Pharma US INC | $22.21 | 2023 | Veozah |
| Kiniksa Pharmaceuticals International, Plc | $20.64 | 2024 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $13.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hung-Sam Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.